Company intelligence / Profile preview

InflaRx

Jena, Thuringia, Germanyorpha.net ↗

Ownership: Public · IFRX
Employees: ~74
Development stage: Commercial

Overview

The company's lead product vilobelimab (GOHIBIC) has received Emergency Use Authorization from the FDA for COVID-19 in hospitalized adults. The company is conducting Phase 3 trials for pyoderma gangrenosum and expects interim analysis in 2025. Phase 2a trials for INF904 in chronic spontaneous urticaria and hidradenitis suppurativa are ongoing with topline data expected in summer 2025.

Therapeutic areas: PulmonologyImmunologyDermatologyOncologyInfectious Diseases
Modalities: Monoclonal antibodiesSmall molecules
Industry: Biotech

Drug pipeline

4 assets

vilobelimab

3 more assets in the full pipeline.

Request access →

Partnerships

Beijing Defengrei Biotechnology Co. Ltd.Merck & Co. Inc.

Financials

Market cap: $319.6M
Total revenue: $0
Enterprise value: $162M

Beyond the preview

Go deeper on InflaRx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InflaRx.

Explore the full profile